Why do patients with Waldenstrom's macroglobulinemia receive plasma exchange therapy?

Patients with Waldenstrom's macroglobulinemia have elevated levels of immunoglobulin M (IgM) in their blood, leading to a condition known as hyperviscosity syndrome. Plasma exchange therapy is utilized specifically to remove excess IgM from the circulation. By reducing the concentration of this abnormal protein, plasma exchange helps alleviate the symptoms and risks associated with increased blood viscosity, such as blurred vision, headache, and neurological issues.

The primary goal of plasma exchange in these patients is to improve circulation and reduce the complications of hyperviscosity, which can impair organ function and lead to serious health complications. Therefore, the rationale behind employing plasma exchange therapy focuses primarily on the removal of excess IgM, directly addressing the underlying issue caused by the disease.